MindMed Secures Patent for MM120 ODT

Mind Medicine (MindMed) Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for mental health disorders, has announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) for their drug MM120 (lysergide). This new patent, USPN 12,036,220, encompasses the pharmaceutical formulation, manufacturing methods, and treatment methods for MM120 ODT, a proprietary and optimized form of lysergide. The patent extends MindMed’s intellectual property protection for MM120 through the year 2041.

MM120 is currently undergoing clinical trials for treating generalized anxiety disorder (GAD) in adults and has potential applications for other brain health disorders. The advanced formulation of MM120 incorporates Catalent’s Zydis® ODT fast-dissolve technology, which MindMed believes will offer significant pharmacological benefits, such as quicker absorption, improved bioavailability, and fewer gastrointestinal side effects. MindMed has exclusive rights to the Zydis technology for lysergide's various forms for pharmaceutical use in several regions, including the United States, the United Kingdom, the European Union, Switzerland, Israel, and Canada.

Rob Barrow, CEO of MindMed, highlighted the significance of the patent issuance, noting that it not only extends IP protection for MM120 but also covers the unique properties of the MM120 ODT formulation. He emphasized the company’s commitment to developing effective treatments that enhance the patient experience. Earlier this year, a pharmacokinetic (PK) bridging study demonstrated the advantageous properties of MM120 ODT, supporting its use in upcoming Phase 3 clinical trials and eventual clinical application upon approval.

MM120, also known as lysergide D-tartrate, is a synthetic ergotamine and a classic serotonergic psychedelic that acts as a partial agonist at human serotonin-2A (5-HT2A) receptors. MindMed is developing MM120 for GAD and exploring its potential for other serious brain health disorders. Given the significant unmet medical need in GAD treatment—especially for patients unresponsive to current medications—along with promising initial clinical data from Phase 2b trials, the U.S. Food & Drug Administration (FDA) has designated MM120 as a breakthrough therapy for GAD. MM120 is set to enter Phase 3 clinical trials in the latter half of 2024, with additional clinical indications under investigation.

Generalized Anxiety Disorder (GAD) is a prevalent condition that impairs millions of people, manifesting as excessive and persistent worry about everyday situations. It affects about 10% of U.S. adults, equating to approximately 20 million individuals. GAD is often underdiagnosed and inadequately treated, leading to significant personal and societal burdens, including reduced workplace productivity and lower labor force participation. Despite the substantial impact of GAD, there has been minimal innovation in its treatment over the past decades, with the last new drug approval occurring in 2007.

MindMed is dedicated to developing new products to address brain health disorders. Their mission is to lead globally in creating and delivering treatments that improve patient outcomes. The company’s pipeline includes various innovative product candidates, some of which target neurotransmitter pathways critical to brain health. MindMed trades on NASDAQ under the symbol MNMD.